Home / Health / AI Wearable Revolutionizes Breast Cancer Screening
AI Wearable Revolutionizes Breast Cancer Screening
24 Sep
Summary
- Radiation-free AI wearable aims for April 2027 commercial launch.
- Final clinical trials set for USA, Great Britain, and Europe in 2027.
- Technology uses thermal sensors and AI for non-invasive cancer detection.
Lord's Mark Industries Limited, in collaboration with C-MET, is progressing its AI-driven, radiation-free breast cancer screening technology toward final clinical trials. These trials are slated to occur in the USA, Great Britain, and Europe, with the aim of achieving commercial launch by April 2027.
The technology employs high-precision thermal sensors and AI for non-invasive abnormality identification. Following successful trials in India, the final clinical evaluations targeting 98% accuracy will commence in January 2027 across India, the USA, Europe, and Great Britain.
This wearable device is designed to be painless, portable, and requires minimal infrastructure, operating on battery power. It holds the potential to significantly expand breast cancer screening accessibility, reaching underserved regions globally.
The company is actively pursuing regulatory approvals in India (CDSCO) and pathways for Europe and the USA, including US FDA. Lord's Mark is targeting key regulatory milestones before March 2027 and commercial placement by April 2027.
Representations have been made to authorities for inclusion in national screening programs and for insurance coverage considerations to enhance affordability and accessibility.
